Fact CheckerSign in

NCT07184034Not yet recruiting

Lipoprotein a Assessment and Relation to Ca Score in CAD Patients Using MSCT

Assessment of the Correlation Between Lipoprotein (a) Levels and Coronary Artery Findings on Multislice Computed Tomography

Source: ClinicalTrials.gov · Last updated 19 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this observational study is to evaluate whether serum Lipoprotein(a) \[Lp(a)\] levels are associated with coronary artery calcium (CAC) score measured by multi-slice computed tomography (MSCT) in adults undergoing cardiac risk assessment. The main questions it aims to answer are: * Is there a correlation between elevated Lp(a) levels and higher CAC scores? * Does Lp(a) provide additional predictive value for subclinical atherosclerosis beyond traditional cardiovascular risk factors? Participants will: * Undergo a non-contrast MSCT scan to measure CAC score. * Provide a blood sample for measurement of Lp(a) and routine lipid profile. * Have baseline clinical and demographic data collected, including cardiovascular risk factors.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
150 (estimated)
First submitted
13 Sept 2025
Start date
Sept 2025
Primary completion date
Sept 2026
Lead sponsor
Assiut University
NCT number
NCT07184034

What you commit to

  • Study type: Observational
  • Planned participants: 150
  • From Sept 2025 to the primary completion date, Sept 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • 1- known CAD or prior revascularization
    • 2-history of myocardial infarction or stroke
    • 3- statin or PCK9 inhibitor use in the past 3 months
    • 4-renal insufficiency (eGFR \< 45ml/min/1.73m2)
    • 5-active inflammation or autoimmune disease

Who the study is looking for

  • 1-adults aged 40-70
    • 2- classified as intermediate cardiovascular risk (10-20% 10 years ASCVD risk)
    • 3-undergoing MsCT for suspected coronary artery disease
    • 4- ability to provide informed consent

Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.